Cited by 433Sexual function and dysfunction studiesHormonal and reproductive studiesMenopause: Health Impacts and Treatments

Testosterone patch for low sexual desire in surgically menopausal women: a randomized trial

Buster, John E., Kingsberg, Sheryl A., Aguirre, Oscar, Brown, Candace, Breaux, Jeffrey G., Buch, Akshay, Rodenberg, Cynthia A., Wekselman, Kathryn +1 more·2005·Obstetrics & Gynecology

Abstract

OBJECTIVE: To assess the efficacy and safety of a 300 mug/d testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women on concomitant estrogen therapy. METHODS: Five hundred thirty-three women with hypoactive sexual desire disorder who had undergone previous hysterectomy and bilateral oophorectomy were enrolled in a 24-week, multicenter, double-blind, placebo-controlled trial. Patients were randomly assigned to receive placebo or the testosterone patch twice weekly. The primary efficacy endpoint was change from baseline at week 24 in the frequency of total satisfying sexual activity, measured by the Sexual Activity Log. Secondary measures included sexual desire using the Profile of Female Sexual Function and personal distress as measured by the Personal Distress Scale. Hormone levels, adverse events, and clinical laboratory measures were reviewed. RESULTS: Total satisfying sexual activity significantly improved in the testosterone patch group compared with placebo after 24 weeks (mean change from baseline, 1.56 compared with 0.73 episodes per 4 weeks, P = .001). Treatment with the testosterone patch also significantly improved sexual desire (mean change, 10.57 compared with 4.29, P < .001) and decreased personal distress (P = .009). Serum free, total, and bioavailable testosterone concentrations increased from baseline. Overall, adverse events were similar in both groups (P > .05). The incidence of androgenic adverse events was higher in the testosterone group; most androgenic adverse events were mild. CONCLUSION: In surgically menopausal women with hypoactive sexual desire disorder, a 300 mug/d testosterone patch significantly increased satisfying sexual activity and sexual desire, while decreasing personal distress, and was well tolerated through up to 24 weeks of use.

Integrity signals

Registry

Crossref · 10.1097/01.aog.0000158103.27672.0d

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Among adult women, endogenous testosterone does not show significant correlations with sexual behavior, but exogenous testosterone treatment in women has been found to increase sexual desire, sexual activity, and sexual self-image.

    “Among adult women, endogenous testosterone does not show significant correlations with sexual behavior (Roney and Simmons, 2013), but exogenous testosterone treatment in women has been found to increase sexual desire, sexual activity, and sexual self-image (Buster et al., 2005, Davis et al., 2006, Shifren et al., 2006).”

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Buster, J. E., Kingsberg, S. A., Aguirre, O., Brown, C., Breaux, J. G., Buch, A., Rodenberg, C. A., Wekselman, K., & Casson, P.
Affiliations
  • Baylor College of Medicine (US)
  • University of Vermont (US)
  • University of Tennessee Health Science Center (US)
  • University Hospitals of Cleveland (US)
Corresponding author
  • Buster, John E.
  • Breaux, Jeffrey G.
Venue
Obstetrics & Gynecology
Published
2005-05
Volume
105
Issue
5, Part 1
Pages
944-952
ISSN
0029-7844 (ISSN-L)
OpenAlex
W2333490567
Cited by
433
References
33
Citations by year
2026: 7 · 2025: 1 · 2024: 4 · 2023: 7 · 2022: 10 · 2021: 9 · 2020: 12 · 2019: 9 · 2018: 20 · 2017: 18 · 2016: 19 · 2015: 11 · 2014: 11 · 2013: 17 · 2012: 31
FWCI
29.48
Type
journal article
Language
en
Open access
closed
Locations
  • Obstetrics and Gynecology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Sexual function and dysfunction studies
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
Keywords
testosterone patch, hypoactive sexual desire disorder, hysterectomy, bilateral oophorectomy, estrogen therapy, sexual desire, sexual activity, personal distress
MeSH terms
Administration, Cutaneous, Adult, Aged, Delayed-Action Preparations, Female, Follow-Up Studies, Humans, Hysterectomy, Libido, Menopause, Middle Aged, Probability, Prognosis, Reference Values, Sexual Behavior, Testosterone, Treatment Outcome, Patient Satisfaction, Risk Assessment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review